Navigation Links
Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
Date:12/5/2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), CareFusion Corporation (NYSE: CFN), and Hologic Inc. (NASDAQ: HOLX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Baxter International Inc. Research Report

On December 2, 2013, Baxter International Inc. (Baxter), along with Halozyme Therapeutics, Inc. (Halozyme), announced that Baxter has completed submission of an amended biologics license application (BLA) to the US Food and Drug Administration (FDA) for re-initiating the review process for approval of HyQvia (Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase) facilitated subcutaneous infusion for the treatment of adults patients with primary immunodeficiency (PI). Baxter stated that the Company and Halozyme submitted additional preclinical data that was requested from the FDA in 2012, and are expecting a six-month review period. Commenting on the release, Ludwig Hantson, Ph.D., President of Baxter's BioScience business, stated, "We believe that if approved, HyQvia may become a valuable option for patients with immune deficiency as it allows for the delivery of a full dose of immunoglobulin often in a single site every three to four weeks, in the comfort of a patient's home." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/163d_BAX

--

WellPoint Inc. Research Report

WellPoint Inc. (WellPoint) posted under "Events & Webcasts" in the Investors section of its website that the Company will participate in the JPMorgan Healthcare Conference on January 14, 2014 at 9:30 a.m. PT in San Francisco, California, US. The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/64cd_WLP

--

Questcor Pharmaceuticals, Inc. Research Report

On December 2, 2013, Questcor Pharmaceuticals, Inc.'s (Questcor Pharmaceuticals) stock closed at $58.75, an increase of 1.28%. Over the past three trading days, the Company's stock went up by 3.93% compared to the Dow Jones Industrial Average which went down by 0.40% during the same trading period. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a415_QCOR

--

CareFusion Corporation Research Report

On December 2, 2013, CareFusion Corporation's (CareFusion) stock went up by 0.65% as it closed the day at $40.11. The Company's stock went up by 0.85% over the previous three trading sessions, compared to the S&P 500 which declined 0.10% during the same trading period. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4933_CFN

--

Hologic Inc. Research Report

On December 2, 2013, Hologic Inc.'s (Hologic) stock declined by 0.36% and closed the day at $22.31. Over the previous three trading days, the Company's stock went down by 1.24% compared to the Nasdaq Composite which went up by 0.68% during the same trading period. The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d132_HOLX

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

 


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)...   Provista , a proven leader in the supply ... announced Jim Cunniff as the company,s new president ... experience to Provista, including most recently serving as the president ... . He assumed his new role with Provista on ... for Provista," says Jody Hatcher , president, Sourcing and ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... food ingredient solutions for the food and beverage industry offers Citri-Fi®, a natural ... statements during the purchasing decision process. As a result, labels need to deliver ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... Health and Clinical Integration company, announced today that its iClinic V12.2 solution has ... 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based care ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i ... 2017 Best in KLAS category winner, has named Daniel P. Bullington as chief ... enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel is ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery ... Kevin Sadati, is pleased to announce a new treatment option called Vivace Microneedling. ... their face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling ...
Breaking Medicine News(10 mins):